Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $440
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $415 to $440.
January 24, 2024 | 4:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reaffirmed an Overweight rating on Vertex Pharmaceuticals and raised the price target to $440, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100